{'fraction_non_alphanumeric': 0.032569360675512665, 'fraction_numerical': 0.031363088057901084, 'mean_word_length': 5.535433070866142, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Intralesional interferon‐α for the treatment of bilateral conjunctival mucosa‐associated lymphoid tissue lymphoma

We describe a case of bilateral conjunctival mucosa‐associated lymphoid tissue (MALT) lymphoma in a 14‐year‐old female treated with intralesional interferon‐α. Interferon‐α‐2b was injected three times a week for 6 weeks, then once weekly for 12 weeks. Marked tumor reduction was observed by week 5 of treatment, with complete resolution by week 8. There was no sign of recurrence through 27 months of follow‐up. Intralesional interferon‐α was an effective treatment for this unusual case of conjunctival MALT lymphoma in a very young female. It presents an attractive alternative to traditional treatment modalities in this patient population. Pediatr Blood Cancer 2012; 59: 176–178. © 2011 Wiley Periodicals, Inc.